Physician profile
Daniel P Oneill
NPI 1477533461
$6,570.42
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,546 · 2020: $2,101 · 2021: $646 · 2022: $46.36 · 2023: $133 · 2024: $97.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $230.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,051.05 | 2019-2020 | |
| Chiesi USA, INC. | $722.89 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $685.58 | 2019-2023 | Lifevest |
| Novartis Pharmaceuticals Corporation | $490.96 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $467.69 | 2019-2020 | |
| Amarin Pharma, INC. | $457.93 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $414.78 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $356.17 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $354.26 | 2019-2020 | |
| Boston Scientific Corporation | $193.86 | 2019-2021 | |
| Bardy Diagnostics, INC. | $133.08 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $128.81 | 2019-2020 | |
| Novo Nordisk INC | $125.00 | 2023 | Wegovy |
| Sanofi-Aventis U.S. LLC | $120.66 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $101.75 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $100.33 | 2019-2020 | |
| Gilead Sciences, INC. | $97.46 | 2024 | |
| Philips North America LLC | $86.58 | 2019 | |
| Medtronic Vascular, INC. | $82.45 | 2019-2020 | |
| Abbott Laboratories | $60.67 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $57.89 | 2019 | |
| Cathworks, INC. | $51.46 | 2019 | |
| Vifor Pharma, INC. | $50.62 | 2019 | |
| Braemar Manufacturing, LLC | $41.36 | 2019 | |
| Lundbeck LLC | $39.52 | 2020 | |
| Arbor Pharmaceuticals, INC. | $30.00 | 2019-2020 | |
| Medtronic, INC. | $25.39 | 2021 | |
| Astellas Pharma US INC | $24.70 | 2020 | |
| Terumo Medical Corporation | $17.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Oneill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.